Skip to content
MarketScale
‹ Back to IndustriesSciences

Composite Materials Keep Boats Riding High

Why Use Composites? Materials for the marine industry need to be versatile, durable, strong, and relatively light. This makes composite materials—fibers reinforced with resin—an ideal choice for marine vessel and part construction. Among the many advantages to using this type of material, composites are corrosion-resistant, customizable, and require minimal maintenance while being easy to repair….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share
Composite Materials Keep Boats Riding High

Key takeaways

01

Materials for the marine industry need to be versatile, durable, strong, and relatively light.

02

This makes composite materials—fibers reinforced with resin—an ideal choice for marine vessel and part construction.

03

Among the many advantages to using this type of material, composites are corrosion-resistant, customizable, and require minimal maintenance while being easy to repair….

Why Use Composites?

Materials for the marine industry need to be versatile, durable, strong, and relatively light. This makes composite materials—fibers reinforced with resin—an ideal choice for marine vessel and part construction. Among the many advantages to using this type of material, composites are corrosion-resistant, customizable, and require minimal maintenance while being easy to repair. They also combine enhanced stiffness with the ability to easily engineer structures with complex shapes or geometry. From gratings, ducts, and shafts to piping and hull shells, the high strength-to-weight ratio and robust structure of composite materials has made them incremental to the marine industry for decades.

Comparing Composites

One of the earliest composites used in the marine industry was ferrocement—a matrix of hydraulic cement mortar and layers of continuous steel mesh reinforcements patented in France in 1855. Mostly used in low-cost barges today, ferrocement is inexpensive but susceptible to corrosion. However, for nearly a century now fiber-reinforced composites have been preferred by naval architects and boat builders alike in the manufacturing of marine vessels.

With 95% of the 7 million pleasure boats in existence today constructed with this material, glass-reinforced plastics has been the composite of choice for boat construction since its introduction in the 1950s. In the 1960s, the hand lay-up method was used for mat and woven roving fiberglass, but in the 70s, sandwich construction had taken its place. At the same time, alternative resins like vinyl ester and epoxy were being used. The 1980s saw the introduction of advanced fabrication techniques and, thus, aramid, Kevlar, and carbon fibers were developed. Vacuum-assisted methods and infusion for the production of composites were both introduced in 1990s.

For “hot molded” and “cold molded” vessels, thin veneers of wood/adhesive composites are often laid over the frames to reduce use of aluminum and steel. Aramid fiber is commonly used to strengthen yacht structures and improve shock absorption. Finally, high-performance, lightweight carbon fiber provides a high degree of stability for sailboats and superyacht furniture.

Magnum Venus Products: Build Boats Better

The true advantage of composites is that the end product is more than the sum of its parts, making them more durable, lightweight, and versatile—ideal for shipbuilding and construction. As a premier manufacturer of composite application equipment, Magnum Venus Products (MVP) provides the marine industry the ability for simpler, more efficient boat building.

MVP takes great pride in their foundation as a family-owned business and still adheres to the family values that have made them the industry leader they are today. Affording great respect to their employees, MVP not only values hard work and integrity, but their company culture thrives on creativity, diversity, and innovative thinking.

To learn more about MVP’s gelcoat products used in boats, visit http://www.mvpind.com/productcategory/gelcoat-equipment/ today!

Read more at mvpind.com

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512